Hypermelanoses
Hypermelanosis is not one disease but a spectrum of clinical presentations that share a common feature: too much melanin deposited in the skin. Under the microscope, it falls into two broad groups. In melanocytotic hypermelanosis, the number of pigment cells (melanocytes) is physically increased. In melanotic hypermelanosis, the melanocyte count stays the same, but each cell is overworked and produces melanin at an abnormally high rate.
At the molecular level, the process is switched on by internal and external triggers: ultraviolet (UV) light, high-energy visible (HEV) light, shifts in hormone levels (estrogen/progesterone), or pro-inflammatory cytokines (IL-1, TNF-alpha, leukotrienes) released by injured keratinocytes. These signals bind receptors on the melanocyte surface, most importantly the melanocortin 1 receptor (MC1R), which sets off an intracellular cascade mediated by cyclic AMP (cAMP). The result is increased expression of microphthalmia-associated transcription factor (MITF), the master regulator that drives transcription of the three key enzymes inside the melanosome: tyrosinase, tyrosinase-related protein 1 (TRP-1), and TRP-2.
Overactive tyrosinase speeds the oxidation of L-tyrosine to L-DOPA and then to dopaquinone, the branch point for making either eumelanin (black/brown pigment) or pheomelanin (red/yellow pigment). Once melanosomes are loaded with pigment, a motor complex (myosin Va–melanophilin–Rab27a) carries them along the melanocyte's dendrites and hands them off to neighboring keratinocytes. In more complicated cases, when the basement membrane is damaged or there is intense inflammation in the upper dermis, melanin incontinence occurs: pigment escapes from the epidermis, drops into the dermis, and is engulfed by macrophages. These pigment-laden cells, called melanophages, can persist for years.
At Haute-Derma, we view hypermelanosis as a dynamic response disorder in which pigment production outpaces the skin's ability to clear it. Our approach rejects the idea of simply blasting pigment away with heat. Instead, Haute-Derma uses a strategy of interrupting melanogenesis at multiple points while restoring the basement membrane, acting on at least four biological targets at once so that pigment is cleared at its source without provoking rebound post-inflammatory hyperpigmentation (PIH).
Clinical Classification and Differential Diagnosis of Hyperpigmentation
How deep the pigment sits determines the treatment approach and how long a patient can expect before seeing results:
| Feature | Epidermal Hyperpigmentation | Dermal Hyperpigmentation |
|---|---|---|
| Typical conditions | Epidermal melasma, freckles (ephelides), lentigines, superficial PIH. | Nevus of Hori, nevus of Ota, Riehl melanosis, deep PIH. |
| Clinical color | Light brown to dark brown-black, with well-defined borders. | Ash gray, slate blue, or gray-brown, with blurred borders. |
| Wood's lamp | Lesions become sharper, darker, and more contrasted. | Lesions fade or show no change in contrast. |
| Histopathology | Melanin builds up in the keratinocyte and basal layers; melanocyte density may be increased or normal. | Free melanin accumulates in the superficial/deep dermis or sits inside melanophages around blood vessels. |
Haute-Derma's Combined Multi-Target Treatment Protocol
For difficult mixed-type hyperpigmentation, Haute-Derma treats the skin layer by layer, combining advanced devices with targeted pharmacologic therapy:
Build protection and stabilize the cells: We use broad-spectrum sunscreens that block UV, HEV, and IR-A. Patients also take high-dose oral antioxidants such as glutathione together with Polypodium leucotomos to mop up free radicals and dampen MC1R sensitivity before any laser energy is applied.
Break the melanogenesis chain medically: We prescribe an intensive topical regimen that hits several points at once: high-strength cysteamine or thiamidol (competitive tyrosinase inhibition) + niacinamide 5% (blocks melanosome transfer) + tranexamic acid 3% (inhibits plasminogen activator to cut off inflammatory signaling from keratinocytes).
Target microscopic pigment with picosecond laser: We use a dual-wavelength picosecond Nd:YAG laser (1064 nm for the dermis and 532 nm/585 nm for the epidermis). The photoacoustic effect of ultrashort picosecond pulses shatters pigment clusters and melanophages into ultrafine particles without generating the heat that damages the basement membrane, making it easy for immune macrophages to clear them.
Accelerate natural skin renewal: We use specialized low-strength chemical peels with retinol or mandelic acid for the face and skin folds to speed up epidermal turnover. This pushes pigment-laden keratinocytes to the surface so they shed naturally, leaving a brighter, smoother, more even complexion.
